As Gilead’s PD-1/TIGIT Trial Falls Short, Oncologists Say Better Biomarkers Needed

The ARC-7 trial showed a progression-free survival benefit in NSCLC, but the PFS benefit for zimberelimab/domvanalimab wasn’t as big as analysts and oncologists had hoped.

ASCO 2023 • Source: Alaric DeArment

At the recently concluded American Society of Clinical Oncology meeting, Gilead Sciences, Inc. and Arcus Biosciences, Inc. joined the ranks of firms developing combinations of PD-1 and PD-L1 inhibitors with monoclonal antibodies targeting TIGIT that have not yet lived up to everyone’s expectations in lung cancer.

Lung cancer specialists, meanwhile, hope to see more in the way of biomarkers that might lead to better efficacy for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from ASCO

More from Conferences